Vanguard Group Inc Tempest Therapeutics, Inc. Call Options Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TPST
# of Institutions
34Shares Held
2.4MCall Options Held
44.9KPut Options Held
109K-
Black Rock Inc. New York, NY550KShares$500,7190.0% of portfolio
-
Altium Capital Management LP New York, NY545KShares$495,9500.27% of portfolio
-
Geode Capital Management, LLC Boston, MA220KShares$200,2600.0% of portfolio
-
Fil LTD Hamilton, D0130KShares$117,9160.0% of portfolio
-
Ikarian Capital, LLC Dallas, TX106KShares$96,0960.03% of portfolio
About Tempest Therapeutics, Inc.
- Ticker TPST
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 10,418,900
- Market Cap $9.48M
- Description
- Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxiso...